https://pharminent.com/boehringer-zealands-obesity-drug-more-akin-to-novos-wegovy-in-phase-3/ 2026-04-28T15:42:30Z Pharminent en Boehringer, Zealand's obesity drug 'more akin' to Novo's Wegovy in Phase 3 2026-04-28T14:23:20Z Blog https://pharminent.com/aacr-2026-combo-therapies-by-moderna-marengo-show-promise-in-skin-breast-cancer/ 2026-04-28T15:42:34Z Pharminent en AACR 2026: Combo therapies by Moderna, Marengo show promise in skin, breast cancer 2026-04-28T14:19:24Z Blog https://pharminent.com/lilly-ai-biotech-profluent-ink-2-25b-pact-in-search-of-genetic-medicine-holy-grail/ 2026-04-28T15:42:38Z Pharminent en Lilly, AI biotech Profluent ink $2.25B pact in search of genetic medicine 'holy grail' 2026-04-28T13:30:53Z Blog https://pharminent.com/gsk-eyes-october-fda-verdict-on-chronic-hep-b-drug/ 2026-04-28T15:42:41Z Pharminent en GSK eyes October FDA verdict on chronic hep B drug 2026-04-28T11:39:43Z Blog https://pharminent.com/novartis-shares-fall-as-entresto-sales-weaken/ 2026-04-28T15:42:43Z Pharminent en Novartis shares fall as Entresto sales weaken 2026-04-28T10:24:18Z Blog https://pharminent.com/seaport-and-hemab-target-180m-ipos-as-biotech-listings-accumulate/ 2026-04-28T15:42:46Z Pharminent en Seaport and Hemab target $180m IPOs as biotech listings accumulate 2026-04-28T10:22:38Z Blog https://pharminent.com/boehringer-zealand-dual-acting-drug-causes-16-6-weight-loss/ 2026-04-28T15:42:47Z Pharminent en Boehringer/Zealand dual-acting drug causes 16.6% weight loss 2026-04-28T09:26:41Z Blog https://pharminent.com/biomarin-acquires-amicus-therapeutics-for-4-8bn-2/ 2026-04-28T15:42:48Z Pharminent en BioMarin acquires Amicus Therapeutics for $4.8bn 2026-04-28T08:51:54Z Blog https://pharminent.com/fda-approves-astrazenecas-saphnelo-for-sle-2/ 2026-04-28T15:22:45Z Pharminent en FDA approves AstraZeneca's Saphnelo for SLE 2026-04-28T08:25:11Z Blog https://pharminent.com/rare-disease-gene-therapy/rare-disease-gene-therapy-digest-april-27-2026/ 2026-04-27T21:38:38Z Pharminent en Rare Disease & Gene Therapy Digest • April 27, 2026 2026-04-27T21:38:34Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-april-27-2026/ 2026-04-27T17:40:37Z Pharminent en Strategic News Watch • April 27, 2026 2026-04-27T17:40:33Z Blog https://pharminent.com/oruka-surges-as-long-acting-psoriasis-drug-shows-early-promise/ 2026-04-28T15:22:49Z Pharminent en Oruka surges as long-acting psoriasis drug shows early promise 2026-04-27T16:12:00Z Blog https://pharminent.com/gsk-tesaro-claim-denied-in-jemperli-lawsuit-with-anaptysbio/ 2026-04-27T12:42:25Z Pharminent en GSK/Tesaro claim denied in Jemperli lawsuit with AnaptysBio 2026-04-27T11:22:22Z Blog https://pharminent.com/rejuvenate-crowdfunds-development-of-gene-therapy-for-aging-chronic-diseases/ 2026-04-27T12:32:27Z Pharminent en Rejuvenate crowdfunds development of gene therapy for aging, chronic diseases 2026-04-27T11:06:10Z Blog https://pharminent.com/jj-puts-blockbuster-blood-thinner-xarelto-on-trumprx/ 2026-04-27T12:32:28Z Pharminent en J&J puts blockbuster blood thinner Xarelto on TrumpRx 2026-04-27T10:58:37Z Blog https://pharminent.com/eli-lilly-acquires-ajax-therapeutics-for-first-in-class-jak2-inhibitor-in-myelofibrosis/ 2026-04-27T12:02:15Z Pharminent en Eli Lilly acquires Ajax Therapeutics for first-in-class JAK2 inhibitor in myelofibrosis 2026-04-27T10:45:00Z Blog https://pharminent.com/novartis-secures-pair-of-regulatory-wins-for-skin-disease-and-malaria-treatments-2/ 2026-04-27T12:32:29Z Pharminent en Novartis secures pair of regulatory wins for skin disease and malaria treatments 2026-04-27T10:29:48Z Blog https://pharminent.com/new-nihr-funded-trc-for-parkinsons-disease/ 2026-04-27T12:32:30Z Pharminent en New NIHR-funded TRC for Parkinson's disease 2026-04-27T10:08:15Z Blog https://pharminent.com/lilly-falls-on-slower-start-for-foundayo-versus-wegovy/ 2026-04-27T12:32:31Z Pharminent en Lilly falls on slower start for Foundayo versus Wegovy 2026-04-27T10:06:31Z Blog https://pharminent.com/uk-biotech-could-be-bound-for-recovery-bia-report-reveals/ 2026-04-27T12:32:31Z Pharminent en UK biotech could be bound for recovery, BIA report reveals 2026-04-27T09:55:36Z Blog https://pharminent.com/uk-medicines-regulator-grants-marketing-authorisation-to-enflonsia-for-rsv-prevention/ 2026-04-27T12:32:32Z Pharminent en UK medicines regulator grants marketing authorisation to Enflonsia for RSV prevention 2026-04-27T09:39:40Z Blog https://pharminent.com/sun-pharma-to-acquire-organon-for-11-75bn-2/ 2026-04-27T12:32:32Z Pharminent en Sun Pharma to acquire Organon for $11.75bn 2026-04-27T09:26:02Z Blog https://pharminent.com/sun-sets-out-11-75bn-takeover-play-for-organon/ 2026-04-27T12:32:33Z Pharminent en Sun sets out $11.75bn takeover play for Organon 2026-04-27T09:10:09Z Blog https://pharminent.com/gene-therapy-leaders-aim-to-help-more-baby-kjs-with-novel-regulatory-models/ 2026-04-27T21:13:26Z Pharminent en Gene therapy leaders aim to help more Baby KJs with novel regulatory models 2026-04-27T04:03:00Z Blog